港股早評:三大指數均高開逾1%,科技股普漲,光伏股強勢,創新藥繼續活躍
隔夜美股納指、標普500指數創收盤新高,熱門中概股多數上漲。港股三大指數大幅高開,恆指漲1.06%,國指漲1.05%,恆生科技指數漲1.31%。盤面上,大型科技股集體上漲,其中,阿里巴巴漲2.5%,京東、美團漲近2%,騰訊漲1.55%,小米漲0.62%;光伏股大漲,與中國太保達成戰略合作,協鑫科技漲14.5%表現最佳,新特能源、信義玻璃、福萊特玻璃均上漲;生物醫藥股持續上漲,榮昌生物、泰格醫藥、君實生物漲約3%;鋰電池股、啤酒股、食品飲料股、海運股、腦機概念股齊漲,其中,寧德時代漲2.6%。另一方面,煤炭股、濠賭股、新消費概念股走低,泡泡瑪特跌近1%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.